Safety of platelet transfusion: Past, present and future

Vox Sanguinis

Volumn 107, Issue 2, 2014, Pages 103-113

  Katus, M C ^a   Szczepiorkowski, Z M ^a   Dumont, L J ^a   Dunbar, N M ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Blood collection; Platelet concentrates; Platelet transfusion; Transfusion medicine; Transfusion reactions; Transfusion transmissible infections

Indexed keywords

ACUTE LUNG INJURY; BACTEREMIA; BLOOD GROUP INCOMPATIBILITY; HUMAN; IMMUNOLOGY; MICROBIOLOGY; RISK; SHOCK; THROMBOCYTE; THROMBOCYTE TRANSFUSION;

ACUTE LUNG INJURY; BACTEREMIA; BLOOD GROUP INCOMPATIBILITY; BLOOD PLATELETS; HUMANS; PLATELET TRANSFUSION; RISK; SHOCK;

EID: 84904410561     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12146     Document Type: Article

References (99)

1. Follea G (ed): Blood, Tissue and Cells From Human Origen: The European Blood Alliance Perspective. European Blood Alliance, The Netherlands, 2013
2. Department of Health and Human Services: The 2011 National Blood Collection and Utilization Survey Report. Washington, DC, DHHS, 2013
3. Canadian Blood Service: Complete 2011/2012 Financial Report. Available from: http://video.bloodservices.ca/Annual2012/cbs_ar2012_finreport_en.html (Retrieved 5 December 2013)
4. Sack T, Gibson JG, Buckley ES Jr: The preservation of whole ACD blood collected, stored, and transfused in plastic equipment. Surg Gynecol Obstet 1952; 95:113-119
5. Murphy S, Gardner FH: Effect of storage temperature on maintenance of platelet viability-deleterious effect of refrigerated storage. N Engl J Med 1969; 280:1094-1098
6. Method 6-13. Preparing Platelets from Whole Blood; in Roback JD, Grossman BJ, Harris T, Hillyer CD. (eds): Technical Manual, 17th edn. Bethesda, Maryland, USA, AABB, 2011
7. Murphy S, Heaton WA, Rebulla P: Platelet production in the Old World-and the New. Transfusion 1996; 36:751-754
8. Pearson H, Davis KG, Wood EM, et al.: Logistics of platelet concentrates. Vox Sang 2007; 92:160-181
9. Vamvakas EC: Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 2009; 49:2743-2758
10. Eder AF, Dy BA, Kennedy JM, et al.: The American Red Cross donor hemovigilance program: complications of blood donation reported in 2006. Transfusion 2008; 48:1809-1819
11. van der Meer PF: Platelet concentrates, from whole blood or collected by apheresis? Transfus Apher Sci 2013; 48:129-131
12. Heddle NM, Arnold DM, Boye D, et al.: Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008; 48:1447-1458
13. Triulzi DJ, Assmann SF, Strauss RG, et al.: The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 2012; 119:5553-5562
14. Saidenberg E, Petraszko T, Semple E, et al.: Transfusion-related acute lung injury (TRALI): a Canadian blood services research and development symposium. Transfus Med Rev 2010; 24:305-324
15. Perkins HA, Busch MP: Transfusion-associated infections: 50 years of relentless challenges and remarkable progress. Transfusion 2010; 50:2080-2099
16. Roback JD, Josephson CD: New insights for preventing transfusion-transmitted cytomegalovirus and other white blood cell-associated viral infections. Transfusion 2013; 53:2112-2116
17. Dollard SC, Roback JD, Gunthel C, et al.: Measurements of human herpesvirus 8 viral load in blood before and after leukoreduction filtration. Transfusion 2013; 53:2164-2167
18. Hewitt PE, Davison K, Howell DR, et al.: Human T-lymphotropic virus lookback in NHS Blood and Transplant (England) reveals the efficacy of leukoreduction. Transfusion 2013; 53:2168-2175
19. Ziemann M, Juhl D, Gorg S, et al.: The impact of donor cytomegalovirus DNA on transfusion strategies for at-risk patients. Transfusion 2013; 53:2183-2189
20. Bowden RA, Slichter SJ, Sayers M, et al.: A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995; 86:3598-3603
21. Bloch EM, Lee TH, Krause PJ, et al.: Development of a real-time polymerase chain reaction assay for sensitive detection and quantitation of Babesia microti infection. Transfusion 2013; 53:2299-2306
22. O'Brien SF, Scalia V, Goldman M, et al.: Selective testing for Trypanosoma cruzi: the first year after implementation at Canadian Blood Services. Transfusion 2013; 53:1706-1713
23. Cooper JK, Andrews N, Ladhani K, et al.: Evaluation of a test for its suitability in the diagnosis of variant Creutzfeldt-Jakob disease. Vox Sang 2013; 105:196-204
24. Kakaiya R, Aronson CA, Julleis J: Whole Blood Collection and Component Processing at Blood Collection Centers; in: Roback JD, Grossman BJ, Harris T, et al. (eds): Technical Manual, 17th edn. Bethesda, Maryland, USA, AABB, 2011
25. Ramirez-Arcos S, Goldman M: Bacterial Contamination; in: Popovsky M (ed): Transfusion Reactions, 4th edn. Bethesda, Maryland, USA, AABB Press, 2012
26. Benjamin RJ, Dy B, Warren R, et al.: Skin disinfection with a single-step 2% chlorhexidine swab is more effective than a two-step povidone-iodine method in preventing bacterial contamination of apheresis platelets. Transfusion 2011; 51:531-538
27. Schrezenmeier H, Walther-Wenke G, Muller TH, et al.: Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007; 47:644-652
28. Mohr H, Bayer A, Gravemann U, et al.: Elimination and multiplication of bacteria during preparation and storage of buffy coat-derived platelet concentrates. Transfusion 2006; 46:949-955
29. Holden F, Foley M, Devin G, et al.: Coagulase-negative staphylococcal contamination of whole blood and its components: the effects of WBC reduction. Transfusion 2000; 40:1508-1513
30. Yomtovian R, Brecher ME: pH and glucose testing of single-donor apheresis platelets should be discontinued in favor of a more sensitive detection method. Transfusion 2005; 45:646-648
31. Benjamin RJ, Kline L, Dy BA, et al.: Bacterial contamination of whole-blood-derived platelets: the introduction of sample diversion and prestorage pooling with culture testing in the American Red Cross. Transfusion 2008; 48:2348-2355
32. Dumont LJ, Kleinman S, Murphy JR, et al.: Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion 2010; 50:589-599
33. Murphy WG, Foley M, Doherty C, et al.: Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang 2008; 95:13-19
34. Pearce S, Rowe GP, Field SP: Screening of platelets for bacterial contamination at the Welsh Blood Service. Transfus Med 2011; 21:25-32
35. Larsen CP, Ezligini F, Hermansen NO, et al.: Six years' experience of using the BacT/ALERT system to screen all platelet concentrates, and additional testing of outdated platelet concentrates to estimate the frequency of false-negative results. Vox Sang 2005; 88:93-97
36. Walther-Wenke G, Wirsing von Konig CH, Daubener W, et al.: Working Party on Bacteria Safety in Transfusion Medicine, Advisory Board of the German Ministry of Health, Berlin: monitoring bacterial contamination of blood components in Germany: effect of contamination reduction measures. Vox Sang 2011; 100:359-366
37. Eder AF, Kennedy JM, Dy BA, et al.: American Red Cross Regional Blood Centers: limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. Transfusion 2009; 49:1554-1563
38. Jenkins C, Ramirez-Arcos S, Goldman M, et al.: Bacterial contamination in platelets: incremental improvements drive down but do not eliminate risk. Transfusion 2011; 51:2555-2565
39. Jacobs MR, Smith D, Heaton WA, et al.: Detection of bacterial contamination in prestorage culture-negative apheresis platelets on day of issue with the Pan Genera Detection test. Transfusion 2011; 51:2573-2582
40. Dunbar NM, Kreuter JD, Marx-Wood CR, et al.: Routine bacterial screening of apheresis platelets on Day 4 using a rapid test: a 4-year single-center experience. Transfusion 2013; 53:2307-2313
41. Harm SK, Delaney M, Charapata M, et al.: Routine use of a rapid test to detect bacteria at the time of issue for nonleukoreduced, whole blood-derived platelets. Transfusion 2013; 53:843-850
42. Lee CK, Chan HM, Ho PL, et al.: Long-term clinical outcomes after Streptococcus bovis isolation in asymptomatic blood donors in Hong Kong. Transfusion 2013; 53:2207-2210
43. Palavecino EL, Yomtovian RA, Jacobs MR: Bacterial contamination of platelets. Transfus Apher Sci 2010; 42:71-82
44. Bolton-Maggs PHB (ed), Poles D, Watt A, et al.: Serious Hazards of Transfusion (SHOT) Steering Group: The 2012 Annual SHOT Report. United Kingdom, 2013
45. U.S. Food and Drug Administration: Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year 2012. Washington, DC, DHHS, 2013
46. Prowse CV: Component pathogen inactivation: a critical review. Vox Sang 2013; 104:183-199
47. Lozano M, Cid J: Pathogen inactivation: coming of age. Curr Opin Hematol 2013; 20:540-545
48. Butler C, Doree C, Estcourt LJ, et al.: Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev 2013; 3:CD009072
49. Kleinman S, Reed W, Stassinopoulos A: A patient-oriented risk-benefit analysis of pathogen-inactivated blood components: application to apheresis platelets in the United States. Transfusion 2013; 53:1603-1618
50. Lozano M, Heddle N, Williamson LM, et al.: Practices associated with ABO-incompatible platelet transfusions: a BEST Collaborative international survey. Transfusion 2010; 50:1743-1748
51. Fung MK, Downes KA, Shulman IA: Transfusion of platelets containing ABO-incompatible plasma: a survey of 3156 North American laboratories. Arch Pathol Lab Med 2007; 131:909-916
52. Cooling LL, Downs TA, Butch SH, et al.: Anti-A and anti-B titers in pooled group O platelets are comparable to apheresis platelets. Transfusion 2008; 48:2106-2113
53. Karafin MS, Blagg L, Tobian AA, et al.: ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions. Transfusion 2012; 52:2087-2093
54. Daniel-Johnson J, Leitman S, Klein H, et al.: Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions. Transfusion 2009; 49:1845-1849
55. Quillen K: Hemolysis from platelet transfusion: call to action for an underreported reaction. Transfusion 2012; 52:2072-2074
56. Berseus O, Boman K, Nessen SC, et al.: Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma. Transfusion 2013; 53(Suppl. 1):114S-123S
57. Fontaine MJ, Mills AM, Weiss S, et al.: How we treat: risk mitigation for ABO-incompatible plasma in plateletpheresis products. Transfusion 2012; 52:2081-2085
58. Win N, NBS Transfusion Medicine Clinical Policies Group: High Titre Anti-A/B Testing of Donors within NHS Blood and Transplant (NHSBT). June 2011. Available from: http://hospital.blood.co.uk/library/pdf/INF178.pdf (Retrieved on 5 December 2013)
59. Josephson CD, Castillejo MI, Grima K, et al.: ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies. Transfus Apher Sci 2010; 42:83-88
60. Transfusion of apheresis platelets and ABO groups: Vox Sang 2005; 88:207-221
61. Ashford P, Gulliksson H, Georgsen J, et al.: Standard terminology for platelet additive solutions. Vox Sang 2010; 98:577-578
62. Johnson L, Reid S, Tan S, et al.: PAS-G supports platelet reconstitution after cryopreservation in the absence of plasma. Transfusion 2013; 53:2268-2277
63. Cohn CS, Stubbs JR, Schwartz J, et al.: A Comparison of Adverse Reaction Rates for Platelet Additive Solution 3 (PAS 3) Versus Plasma Platelet Units. Transfusion 2013; 53(Suppl):136A
64. Galloway-Haskins R, Heaton WA, Nikolis NM, et al.: Post PAS 3 Launch Reaction Rates (RR) and Increments at North Shore University Hospital (NSUH). Transfusion 2013; 53(Suppl):190A
65. U.S. Food and Drug Administration: Approval Letter - InterSol. Washington, DC, DHHS, 2009
66. Dumont LJ, Cancelas JA, Graminske S, et al.: In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution. Transfusion 2013; 53:972-980
67. Quillen K, Sheldon SL, Daniel-Johnson JA, et al.: A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies. Transfusion 2011; 51:92-96
68. Goldman M, Webert KE, Arnold DM, et al.: TRALI Consensus Panel: proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005; 19:2-31
69. Toy P, Gajic O, Bacchetti P, et al.: Transfusion-related acute lung injury: incidence and risk factors. Blood 2012; 119:1757-1767
70. Ramanathan RK, Triulzi DJ, Logan TF: Transfusion-related acute lung injury following random donor platelet transfusion: a report of two cases. Vox Sang 1997; 73:43-45
71. Eder AF, Herron RM Jr, Strupp A, et al.: Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion 2010; 50:1732-1742
72. Eastlund DT, McGrath PC, Burkart P: Platelet transfusion reaction associated with interdonor HLA incompatibility. Vox Sang 1988; 55:157-160
73. Reesink HW, Lee J, Keller A, et al.: Measures to prevent transfusion-related acute lung injury (TRALI). Vox Sang 2012; 103:231-259
74. Lin Y, Saw CL, Hannach B, et al.: Transfusion-related acute lung injury prevention measures and their impact at Canadian Blood Services. Transfusion 2012; 52:567-574
75. Sayah DM, Looney MR, Toy P: Transfusion reactions: newer concepts on the pathophysiology, incidence, treatment, and prevention of transfusion-related acute lung injury. Crit Care Clin 2012; 28:363-72
76. Murphy EL, Kwaan N, Looney MR, et al.: Risk factors and outcomes in transfusion-associated circulatory overload. Am J Med 2013; 126:357.e29-357.e38
77. Lockwood WB, Leonard J, Liles SL: Storage, Monitoring, Pretransfusion Processing, and Distribution of Blood Components; in: Roback JD, Grossman BJ, Harris T, Hillyer CD. (eds): Technical Manual, 17th edn. Bethesda, MD, USA, AABB, 2011
78. Geiger TL, Howard SC: Acetaminophen and diphenhydramine premedication for allergic and febrile nonhemolytic transfusion reactions: good prophylaxis or bad practice? Transfus Med Rev 2007; 21:1-12
79. Hirayama F: Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Br J Haematol 2013; 160:434-444
80. Heddle NM, Blajchman MA, Meyer RM, et al.: A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion 2002; 42:556-566
81. The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337:1861-1869
82. Seftel MD, Growe GH, Petraszko T, et al.: Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004; 103:333-339
83. Byrne D. Commission of European Communities Directive 2004/33/EC: Technical requirements for blood and blood components. Off J Eur Union 2004; L91: 25-39
84. Carson TH: Standard 5.7.4.1 Leukocyte Reduction; in Standards for Blood Banks and Transfusion Services, 28th Edn. Bethesda, Maryland, USA, AABB, 2012
85. Dwyre DM, Holland PV: Transfusion-associated graft-versus-host disease. Vox Sang 2008; 95:85-93
86. Treleaven J, Gennery A, Marsh J, et al.: British Committee for Standards in Haematology blood transfusion task force: guidelines on the use of irradiated blood components. Br J Haematol 2011; 152:35-51
87. Fast LD: Developments in the prevention of transfusion-associated graft-versus-host disease. Br J Haematol 2012; 158:563-568
88. O'Brien KL, Pereira SE, Wagner J, et al.: Transfusion-associated graft-versus-host disease in a liver transplant recipient: an unusual presentation and review of the literature. Transfusion 2013; 53:174-180
89. Asai T, Inaba S, Ohto H, et al.: Guidelines for irradiation of blood and blood components to prevent post-transfusion graft-vs.-host disease in Japan. Transfus Med 2000; 10:315-320
90. Moroff G, Luban NL: The irradiation of blood and blood components to prevent graft-versus-host disease: technical issues and guidelines. Transfus Med Rev 1997; 11:15-26
91. Shehata N, Tinmouth A, Naglie G, et al.: ABO-identical versus nonidentical platelet transfusion: a systematic review. Transfusion 2009; 49:2442-2453
92. Henrichs KF, Howk N, Masel DS, et al.: Providing ABO-identical platelets and cryoprecipitate to (almost) all patients: approach, logistics, and associated decreases in transfusion reaction and red blood cell alloimmunization incidence. Transfusion 2012; 52:635-640
93. van der Meer PF, Bontekoe IJ, Kruit G, et al.: Volume-reduced platelet concentrates: optimization of production and storage conditions. Transfusion 2012; 52:819-827
94. Perseghin P: High concentration plasma-reduced plateletapheresis concentrates. Transfus Apher Sci 2011; 44:273-276
95. Dumont LJ, Cancelas JA, Dumont DF, et al.: A randomized controlled trial evaluating recovery and survival of 6% dimethyl sulfoxide-frozen autologous platelets in healthy volunteers. Transfusion 2013; 53:128-137
96. Modery-Pawlowski CL, Tian LL, Pan V, et al.: Approaches to synthetic platelet analogs. Biomaterials 2013; 34:526-541
97. Cap AP, Perkins JG: Lyophilized platelets: challenges and opportunities. J Trauma 2011; 70:S59-60
98. Fitzpatrick GM, Cliff R, Tandon N: Thrombosomes: a platelet-derived hemostatic agent for control of noncompressible hemorrhage. Transfusion 2013; 53(Suppl. 1):100S-106S
99. Reems JA, Pineault N, Sun S: In vitro megakaryocyte production and platelet biogenesis: state of the art. Transfus Med Rev 2010; 24:33-43